Outcomes of MicroPulse^® Transscleral Laser Therapy Using the Revised MicroPulse P3^® Delivery Device

Area of Science:

• Ophthalmology
• Glaucoma treatment
• Laser therapy

Background:

• Glaucoma management requires effective intraocular pressure (IOP) reduction.
• MicroPulse® transscleral laser therapy (MP-TLT) is an established treatment modality.
• Evaluating new delivery devices for laser therapy is crucial for improving patient outcomes.

Purpose of the Study:

• To compare the safety and efficacy of the revised MicroPulse P3® (MP3) probe versus the original probe for MP-TLT.
• To assess the long-term IOP-lowering effects and adverse event rates.

Main Methods:

• Retrospective study of 122 eyes from 99 glaucoma patients undergoing MP-TLT.
• Comparison between eyes treated with the original MP3 probe (95 eyes) and the revised MP3 probe (27 eyes).
• Primary outcome: success at 12 months (IOP <18 mm Hg with >20% reduction or medication decrease, no adverse events/secondary surgical interventions).

Main Results:

• The revised probe group showed a trend towards greater IOP reduction (29.7% vs 21.4%) and lower mean IOP at 12 months (14.8 vs 17.9 mm Hg).
• Success rates at 12 months were similar (40.7% revised vs 32.6% original).
• No significant difference in adverse events or secondary surgical interventions; however, fewer repeat MP-TLT procedures were needed with the revised probe.

Conclusions:

• The revised MP3 probe may offer improved and more sustained IOP reduction compared to the original probe.
• MP-TLT with the revised probe maintains an excellent safety profile.
• Further research may validate the enhanced efficacy of the revised probe in glaucoma management.